Novi Weight Loss GLP-1 Program (2026): What 50,000 People Searching This Brand Need to Know Before Enrolling
Compounded Semaglutide and Tirzepatide Pricing, the FAQ vs. Terms of Service Cancellation Conflict Most Sites Won't Show You, Eligibility Requirements, and the 2026 FDA Regulatory Reality Every Prospective Patient Should Understand
SHERIDAN, WY / ACCESS Newswire / April 8, 2026 / This is paid promotional content. It is intended to help readers evaluate publicly available information about Novi's telehealth weight loss program, including its pricing, process, eligibility requirements, and current regulatory context. It is not independent medical advice, not a guarantee of eligibility or results, and not a substitute for speaking with a licensed healthcare professional.
Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. This is not medical advice - consult a qualified healthcare professional before making health decisions.
Novi GLP-1 Review 2026: Cost, Safety, and Real Results
If you have been researching telehealth GLP-1 programs and the name Novi keeps showing up in your feed, you are far from alone. The compounded GLP-1 space has exploded over the past two years, and with that growth has come a flood of questions from people trying to separate real information from marketing noise.
Many readers searching for terms like "Novi GLP-1," "semaglutide online," "compounded tirzepatide telehealth," or "weight loss injections without insurance" are trying to understand more than just pricing. They want to know whether programs like this one are legitimate, how the medical process actually works, what the FDA's current enforcement stance means for compounded medications, and what risks or limitations they should weigh before spending a dollar. This article addresses those questions directly.
What you will not find here is a verdict at the bottom of the page telling you what to do. What you will find is enough verified detail - pulled from Novi's own website, its Terms of Service, published clinical research, and current FDA guidance - to make that decision yourself. That is exactly how a choice involving prescription medication should work.
Review Novi's current program details, pricing, and eligibility on the official Novi website
What This Article Is and What It Is Not
This is paid promotional content published to help readers evaluate publicly available information about Novi's GLP-1 telehealth program. It is not an independent clinical evaluation. It does not constitute medical advice, a diagnosis, or a treatment recommendation. And it is not a substitute for sitting down with a licensed healthcare professional who can assess whether GLP-1 therapy makes sense for your specific health situation.
References to published clinical studies on FDA-approved semaglutide and tirzepatide are included strictly as educational context about the GLP-1 therapeutic class. They should not be interpreted as proof of equivalent outcomes for any compounded product, telehealth program, or individual patient.
How Novi's Telehealth Program Works: The Three-Entity Structure
Understanding who does what inside a telehealth GLP-1 program matters more than most marketing pages suggest. Novi operates using a three-entity structure that is common across the telehealth weight loss space - but the distinctions between those entities carry real implications for your care.
Novi International LLC (the Platform) functions as the telehealth technology and coordination layer. According to its own Terms of Service, Novi states that it does not provide medical advice or medical care. The platform facilitates the intake process, manages customer support, handles billing, and coordinates the logistics between you, a clinician, and a pharmacy. Novi is not itself a healthcare provider.
Licensed Medical Providers (Independent Clinicians) are the professionals who review your health information and determine whether a GLP-1 prescription is appropriate. According to Novi's website, the clinical team includes board-certified physicians and nurse practitioners. These clinicians make the prescribing decision independently. The platform cannot guarantee that any individual will receive a prescription - that determination rests entirely with the evaluating clinician.
Partner Pharmacies (Licensed U.S. Pharmacies) fulfill prescriptions written by the medical providers. According to the company, medications are sourced from licensed U.S. pharmacies. These are the entities that compound and dispense the medication you receive.
Why does this matter? Because the marketing you see on Novi's homepage is produced by the platform company - not by the clinicians who will evaluate your health, and not by the pharmacies that prepare the medication. Keeping that distinction in mind helps you evaluate the program's claims with appropriate context.
Compounded GLP-1 Medications: What You Need to Understand About Regulatory Status
This is one of the most important sections in this article, and it appears here intentionally - before pricing, before the enrollment process, and before any discussion of potential outcomes.
Novi's program involves compounded prescription medications. Compounded medications are not reviewed or approved by the FDA as finished products. They are prepared by licensed pharmacies based on individual prescriptions, subject to applicable federal and state compounding regulations.
The FDA-approved branded versions of these medications - Wegovy and Ozempic (semaglutide, manufactured by Novo Nordisk) and Zepbound and Mounjaro (tirzepatide, manufactured by Eli Lilly) - went through rigorous clinical trials and FDA review for safety, effectiveness, and quality. Compounded versions have not undergone that same review process.
The regulatory environment surrounding compounded GLP-1 medications has shifted dramatically. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Since those resolutions, the agency has taken an increasingly restrictive enforcement posture toward mass-marketed compounded GLP-1 products. In February 2026, the FDA announced intentions to restrict the ingredients used in mass-marketed compounded GLP-1 drugs and to crack down on misleading advertising across the space. As recently as April 2026, the FDA issued additional reminders to compounding pharmacies about the legal limits of their statutory exemptions.
The FDA has specifically stated that direct-to-consumer marketing cannot claim compounded GLP-1s are generic, equivalent to, or produce identical outcomes as FDA-approved drugs. The agency has issued warning letters to telehealth companies whose advertising implied equivalence - including flagging language as seemingly routine as referencing "the same active ingredient."
What this means for you as a reader evaluating Novi: the compounded medications available through this program are legally distinct from the FDA-approved branded versions. Whether compounded versions deliver equivalent therapeutic results has not been established through the same standard of clinical evidence. This is not a judgment on Novi specifically - it is the regulatory reality that applies to every telehealth platform offering compounded GLP-1 medications in 2026.
Readers should consult a qualified healthcare professional before starting any weight-loss program or prescription treatment.
What Novi Says Its Program Includes
According to the company's website, the Novi program includes the following elements for eligible patients:
A licensed clinician reviews your intake information and determines whether a tele-visit is needed. If a prescription is deemed appropriate by the evaluating clinician, the company states that you receive a 4-week supply delivered monthly, along with the supplies needed for administration. According to Novi, the program also includes unlimited support from clinicians for check-ins, dose adjustments, and questions, plus coaching at no additional cost.
The company describes its pricing as "all-in and transparent - no hidden fees, no separate membership, medication included."
The enrollment process, as described on the website, follows three steps:
Step 1: Complete an online pre-approval quiz, which the company states takes approximately 3 minutes.
Step 2: Meet with a U.S.-based licensed provider who evaluates your health information and determines the appropriate treatment path.
Step 3: If prescribed, receive your medication with what the company describes as free 2-day shipping.
One detail worth emphasizing: completing the intake quiz does not guarantee a prescription. Only the evaluating clinician can make that determination, and the clinician may decide that GLP-1 treatment is not appropriate for your specific situation.
Current Pricing: What to Verify Before You Enroll
Pricing is one of the most searched aspects of any telehealth GLP-1 program - and one of the areas where you need to exercise the most caution.
At the time of this publication (April 2026), Novi's promotional landing page displayed the following pricing:
Compounded Semaglutide: According to the website, pricing starts from $133 per month, described as reflecting a $200 promotional discount.
Compounded Tirzepatide: According to the website, pricing starts from $166 per month.
The company describes these as including free shipping with no long-term commitment. However - and this is important - the pricing shown on promotional pages may differ from pricing displayed elsewhere on Novi's website. Promotional landing pages and the main homepage can present different figures depending on when and how you access the site.
A necessary reminder: lower pricing does not indicate equivalence in clinical outcomes, regulatory status, or formulation compared to FDA-approved medications. The cost difference between compounded and branded GLP-1 products may reflect differences in manufacturing processes, regulatory review, and clinical trial validation - not simply a better deal on the same product.
Before committing, verify the exact pricing on the specific page you are enrolling through. Confirm whether that price includes all costs (medication, shipping, clinician access). And check whether promotional pricing is subject to any conditions, time limitations, or automatic renewal terms.
Check current Novi pricing, eligibility, and program terms on the official website
The FAQ vs. Terms of Service Conflict: Read This Before You Enroll
Important: Novi's FAQ and Terms of Service present materially different language regarding commitment and cancellation. This section breaks down exactly what each document says - because understanding this discrepancy could save you from an unexpected financial obligation.
What the FAQ says about cancellation: According to Novi's FAQ page, "You can cancel your Novi subscription at any time. Our program is month-to-month with no minimum commitments or long-term contracts, so cancellation is simple and flexible."
What the Terms of Service say about commitment: According to Novi's Terms of Service, "Subscription based Products and/or Services require a minimum 3-month commitment as We incur significant upfront cost to provide these Products and/or Services to you. By enrolling in Subscription Services, you agree to pay for a minimum of three (3) consecutive months of Service."
The Terms further state: "you agree that the first month's fee as well as the monthly fee for the following two months (for a total of three (3) consecutive months) is charged at the time of purchase and is non-refundable."
Additionally, per the Terms: "False credit card disputes will be aggressively defended and customers who attempt to dispute charges to circumvent the 3-month commitment will be sent to collections and/or have further legal action pursued."
These are not interpretations or assumptions. These are the company's own published documents, and they present conflicting language on a fundamental enrollment question. The governing Terms of Service - not the FAQ - typically control the legal relationship between you and the platform. Review both documents carefully before committing any payment information.
The Refund Policy: Know the Fine Print
According to the company's published refund policy: "due to the nature of our products, we are unable to accept returns." The FAQ separately notes that "once a prescription has been dispensed or shipped, it can't be returned or refunded; cancellation will stop future renewals."
Combined with the 3-month commitment language in the Terms of Service, this means that once you enroll and your prescription is dispensed, your total financial obligation may be considerably larger than the FAQ's month-to-month framing initially suggests.
Confirm the exact current cancellation and refund terms directly on the official website - and consider contacting the company's support team for written clarification - before completing enrollment.
Clinical Context: What Published Research Says About the GLP-1 Therapeutic Class
Clinical studies on FDA-approved semaglutide and tirzepatide help explain why GLP-1 medications have attracted significant clinical and consumer attention. These studies describe the therapeutic class and should not be read as proof of outcomes for any specific telehealth program, compounded formulation, or individual patient.
Semaglutide - The STEP Clinical Trial Program: The landmark STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with overweight or obesity who did not have diabetes. Over 68 weeks, participants receiving 2.4 mg of FDA-approved subcutaneous semaglutide experienced a mean weight change of approximately 14.9%, compared with 2.4% in the placebo group. More than 86% of participants in the semaglutide group achieved at least 5% weight reduction. Across the broader STEP program (STEP 1, 3, 4, and 8), mean weight loss with semaglutide ranged from approximately 14.9% to 17.4% from baseline over 68 weeks. The study population was predominantly female (approximately 74%) and White (approximately 75%), which limits the generalizability of results to broader populations.
Tirzepatide - The SURMOUNT Clinical Trial Program: The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight who did not have diabetes. Over 72 weeks, participants receiving FDA-approved tirzepatide achieved mean weight reductions ranging from approximately 16% at the 5 mg dose to approximately 22.5% at the 15 mg dose, compared with 2.4% in the placebo group. At the highest dose, approximately 63% of participants achieved 20% or greater weight loss. The more recent SURMOUNT-5 head-to-head trial directly compared tirzepatide to semaglutide and found tirzepatide produced greater weight reduction over 72 weeks (approximately 20.2% vs. 13.7%).
The critical distinction: These results were achieved with FDA-approved branded medications in controlled clinical trial settings that included lifestyle intervention, regular medical monitoring, and specific dosing protocols. They do not establish identical outcomes for compounded formulations, telehealth programs, or individual patients outside those trial conditions. The FDA has explicitly stated that marketers cannot use these study results to imply that compounded products will produce equivalent results.
The GLP-1 mechanism of action involves mimicking incretin hormones that regulate appetite signaling, gastric emptying, and food intake. These medications work on biological pathways that affect hunger, satiety, and food reward - which is why the therapeutic class has generated substantial clinical interest beyond its original diabetes indications. New delivery formats for FDA-approved GLP-1 medications continue to expand, potentially offering additional access options for patients beyond the traditional injectable route.
References to FDA-approved semaglutide and tirzepatide studies are included for therapeutic context only and should not be interpreted as proof of equivalent outcomes for any compounded product or telehealth program.
Who Is on Novi's Clinical Team
According to the company's website, Novi's clinical team includes several named providers:
Daniel Funsch, MD, is described as board-certified by the American Board of Emergency Medicine. Michael Wasef, MD, is described as board-certified by the American Board of Internal Medicine. Takashi Nakamura, MD, is described as board-certified by the American Board of Emergency Medicine. Kimberli Hastings, NP, is described as certified by the American Academy of Nurse Practitioners. Kristine Clements, NP, is described as a board-certified family nurse practitioner with over 25 years of healthcare experience, including service as a flight medic in the U.S. Air Force. Theresa Vergara, NP, is described as a Certified Nurse Practitioner with a Doctorate in Nursing.
Listing named providers with specific board certifications is a transparency element that not all telehealth platforms offer. That said, the specific clinician who reviews your intake may or may not be one of the providers featured on the website - telehealth platforms commonly have additional clinicians beyond those highlighted in their marketing materials.
Common Side Effects of GLP-1 Medications: What the Research Shows
GLP-1 receptor agonists, as a therapeutic class, are associated with a well-documented side effect profile based on published clinical trial data for the FDA-approved versions. The following is general educational information - not a complete list of risks or precautions.
The most commonly reported side effects in clinical trials of FDA-approved semaglutide and tirzepatide included nausea, diarrhea, vomiting, constipation, and abdominal pain. These were typically mild to moderate in severity, most common during the dose escalation period, and tended to decrease over time as the body adjusted.
More serious but less common risks identified in clinical trials or post-marketing surveillance of FDA-approved GLP-1 medications include pancreatitis, gallbladder problems, kidney issues, and potential thyroid risks. In rodent studies, semaglutide was associated with thyroid C-cell tumors, though the relevance to humans has not been established.
The FDA has also received adverse event reports related to compounded versions of semaglutide and tirzepatide, including reports involving dosing beyond what appears in the FDA-approved drug label. The agency has noted that adverse events from compounded versions are likely underreported, because federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse event reports to the FDA.
Only a licensed clinician can determine whether GLP-1 treatment is appropriate for your specific case. This safety overview is not exhaustive and does not replace the prescribing information provided with any medication. Always discuss your full medical history, current medications, and health concerns with the evaluating clinician before starting treatment.
Who Novi's Program May Align Well With - and Who Should Look Elsewhere
Novi May Align Well With People Who:
Are looking for a cash-pay telehealth option for GLP-1 access: If you do not have insurance coverage for branded GLP-1 medications and are comfortable with compounded alternatives, Novi's publicly displayed pricing may represent a lower upfront cost compared to some alternatives. However, you should understand the regulatory distinctions between compounded and FDA-approved products, and lower pricing does not indicate equivalent clinical outcomes.
Value a structured telehealth process with named clinicians: The company provides transparency about its clinical team, and the three-step process (quiz, clinician evaluation, prescription if appropriate) follows the standard telehealth model for GLP-1 access.
Prefer an all-inclusive monthly pricing model: According to the company, the monthly fee covers medication, shipping, clinician access, and coaching - which simplifies the cost picture compared to managing separate bills across multiple providers.
Want the convenience of home-delivered medication: For people whose schedules, mobility, or geographic location make in-person weight management visits difficult, telehealth delivery removes a practical barrier to treatment access.
Other Options May Be Preferable For People Who:
Want FDA-approved branded medications specifically: If receiving an FDA-approved finished product is important to you, explore platforms that offer branded Wegovy, Zepbound, or other FDA-approved options - or work with your own physician and insurance provider. New FDA-approved delivery formats, including oral options, have also expanded access to branded GLP-1 treatment.
Have complex medical histories: If you take multiple medications, have a history of pancreatitis, thyroid conditions, or other serious health issues, an in-person relationship with an endocrinologist or obesity medicine specialist may provide more thorough evaluation than a telehealth-first model can offer.
Are uncomfortable with the FAQ vs. Terms discrepancy on commitment: If the conflicting cancellation language concerns you, contact Novi's support team directly to get written clarification on your specific commitment terms before enrolling - or consider platforms with clearer and more consistent published terms.
Have insurance that covers GLP-1 medications: If your health plan covers branded GLP-1 medications, the out-of-pocket cost through insurance may be comparable to or lower than cash-pay compounded options - and you would receive an FDA-approved product with established clinical trial backing.
Questions to Ask Yourself Before Enrolling in Any GLP-1 Program
Before choosing any telehealth GLP-1 program - Novi or otherwise - take a few minutes to honestly consider:
Have you discussed weight management and GLP-1 options with your own physician or a qualified healthcare professional?
Are you comfortable receiving a compounded medication rather than an FDA-approved finished product, and do you understand what that distinction means for safety, efficacy, and regulatory standing?
Have you reviewed both the FAQ and the Terms of Service on the specific platform you are considering - not just the marketing page?
Have you verified the exact pricing on the page you are enrolling through, including any promotional conditions, automatic renewal terms, or minimum commitment requirements?
Is your state eligible for the platform's services, and are you comfortable with a cash-pay model where insurance reimbursement is not guaranteed?
Do you have health conditions, medications, or a medical history that would benefit from evaluation by a specialist rather than through a telehealth intake process?
Your answers help determine whether this type of program - and this specific platform - fits your individual health situation, your financial circumstances, and your comfort level with the regulatory landscape surrounding compounded GLP-1 medications.
State Availability and Insurance Considerations
According to Novi's Terms of Service, services are limited exclusively to users located in states within the United States where the program is available. Services are not available to users located outside the United States.
The company does not publish a comprehensive list of eligible states on its public-facing pages as of this publication date. Verify your state's eligibility during the intake process or by contacting the company's customer support team.
Regarding insurance: according to the company, all Novi prescriptions are cash-pay. The company states that insurance may reimburse for branded options, and that compounded medications are "intentionally priced to be affordable without insurance." Many direct-to-consumer prescription programs operate outside traditional insurance networks, but coverage policies vary by plan. Always confirm benefits directly with your insurer. Some HSA/FSA plans may reimburse qualifying medical expenses - check your specific plan rules.
Florida Weight-Loss Consumer Bill of Rights
Florida law (Section 501.0575, Florida Statutes) provides specific consumer protections for weight-loss programs, including required disclosures about the risks of rapid weight loss, the right to receive itemized pricing, and the right to ask about the qualifications of any dietitian or nutritionist involved. Readers in Florida - or any state - should consult a qualified healthcare professional before starting any weight-loss program or prescription treatment.
Contact Information
For questions before or during the enrollment process, according to the company's published pages, Novi offers the following contact options:
Email: [email protected]
Phone: 214-427-4553
Customer Support Center: According to the company, support is available 7 days a week.
Mailing Address: Novi International LLC, 30 N Gould St Ste R, Sheridan, WY 82801
Review current Novi program details, eligibility, and enrollment terms on the official website
Frequently Asked Questions
Is Novi a healthcare provider?
According to Novi's own Terms of Service, Novi International LLC is not a healthcare provider. The platform connects users with independent licensed clinicians who make prescribing decisions. Medical determinations - including whether to prescribe GLP-1 medication - are made by the evaluating clinician, not by the platform.
Are compounded GLP-1 medications the same as FDA-approved versions?
No. Compounded GLP-1 medications are prepared by licensed pharmacies based on individual prescriptions. They are not reviewed or approved by the FDA as finished products. While they may use active pharmaceutical ingredients found in FDA-approved medications, the compounded finished products have not undergone the same clinical trial process for safety, effectiveness, and quality. The FDA has explicitly stated that marketers cannot claim compounded versions are equivalent to FDA-approved drugs.
How much does Novi cost per month?
According to the company's promotional page as of April 2026, compounded semaglutide starts from $133 per month and compounded tirzepatide starts from $166 per month. These appear to reflect promotional pricing. Pricing is subject to change - verify the current pricing on the specific page you are enrolling through before completing your purchase.
Can I cancel Novi at any time?
The company's FAQ states that the program is "month-to-month with no minimum commitments." However, the company's Terms of Service reference a "minimum 3-month commitment" with the first three months charged at the time of purchase and described as non-refundable. Review both documents and contact the company directly for clarification on current enrollment terms before committing.
What happens if the clinician decides I am not eligible?
According to the Terms of Service, if Novi is unable to provide a prescription because treatment is deemed medically inappropriate, the company states it will refund your initial payment to your original method of payment.
What clinical evidence supports GLP-1 medications for weight management?
Published clinical trials on FDA-approved semaglutide (the STEP program) and FDA-approved tirzepatide (the SURMOUNT program) have demonstrated significant weight reduction in participants with overweight or obesity. These studies provide context for the therapeutic class but do not establish identical outcomes for compounded formulations or any specific telehealth program. Individual eligibility, dosing, tolerance, and outcomes vary and should be discussed with a licensed clinician.
Is Novi legitimate?
Novi International LLC is a registered company that operates a telehealth platform connecting users with licensed clinicians and licensed U.S. pharmacies. The company references third-party compliance certifications on its website. Readers evaluating any telehealth platform should independently verify any certifications, licensing, and regulatory claims before enrolling.
How does Novi compare to other GLP-1 telehealth platforms?
This article evaluates Novi's program on its own merits - its pricing, process, regulatory context, and published terms - rather than making comparative claims about competing platforms. Each telehealth GLP-1 provider operates under its own pricing structure, pharmacy partnerships, clinician network, and terms of service. Readers should evaluate multiple options and verify current details directly before making any enrollment decision.
Important Regulatory Context for 2026 and Beyond
The compounded GLP-1 telehealth industry has been under increased regulatory scrutiny throughout 2025 and into 2026. The FDA has issued warning letters and enforcement actions targeting misleading advertising in the compounded GLP-1 space, restricted compounding pathways as branded drug shortages have resolved, and signaled continued enforcement focus going forward. As of April 2026, neither semaglutide nor tirzepatide appears on the FDA's drug shortage list, which narrows the legal basis under which many compounding pharmacies have been operating.
Readers should review the most current information about any telehealth platform's compliance, quality standards, and regulatory standing before enrolling. This regulatory environment is actively evolving, and the legal landscape for compounded GLP-1 medications may continue to shift in ways that affect availability, pricing, and program structures.
See the current Novi program offer, pricing, and enrollment details on the official website
The Bottom Line
Novi's telehealth GLP-1 program offers a cash-pay pathway to compounded semaglutide and tirzepatide through licensed clinicians and U.S. pharmacies. Based on its publicly displayed pricing at the time of this publication, the program represents a lower-priced entry point in the compounded GLP-1 space.
But cost is only one factor in a decision that involves prescription medication. The regulatory distinction between compounded and FDA-approved products, the rapidly evolving FDA enforcement landscape, the discrepancy between the company's FAQ and Terms of Service on commitment and cancellation, and the inherent limitations of any telehealth-first evaluation model all belong in your decision-making process.
The strongest version of that decision happens when you take this information - along with your own health history, weight management goals, and questions - to a licensed healthcare professional who can evaluate whether GLP-1 treatment is appropriate for your specific situation. No telehealth landing page, no promotional article, and no marketing claim should be a substitute for that conversation.
Review Novi's current program, eligibility requirements, and terms on the official Novi website
Disclaimer Bundle
Content and Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The descriptions of potential benefits are not guarantees and are not a substitute for an individualized medical evaluation. Medications discussed in this article are compounded prescription medications that require evaluation by a licensed clinician. The information provided here does not replace the professional judgment of your healthcare provider.
Professional Medical Disclaimer: This article is educational and does not constitute medical advice. Compounded GLP-1 medications are not a substitute for prescribed medical treatment. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting any new prescription treatment. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval.
Compounded Medication Notice: Medications referenced in this article include compounded prescription medications prepared by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products. They are prepared by licensed pharmacies under the direction of a prescribing clinician, subject to applicable compounding regulations. The FDA has stated concerns about unapproved compounded GLP-1 drugs and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Results May Vary: Individual results will vary based on factors including age, baseline health condition, body composition, metabolic factors, consistency of use, genetic factors, current medications, lifestyle factors, and other individual variables. Clinical trial results cited in this article were achieved with FDA-approved branded medications in controlled trial settings and do not establish equivalent outcomes for compounded formulations or telehealth programs. Results are not guaranteed.
FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on published research and publicly available information.
Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were based on publicly available information at the time of publication (April 2026) and are subject to change without notice. Promotional pricing may differ from standard pricing displayed elsewhere on the website. Always verify current pricing, promotional conditions, and terms on the official Novi website before making your purchase.
Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with Novi and their healthcare provider before making decisions.
Insurance Coverage Note: Many direct-to-consumer prescription products are not covered by traditional insurance plans, but coverage policies vary. Always confirm benefits directly with your insurer. Some HSA/FSA plans may reimburse qualifying expenses; check your specific plan rules.
SOURCE: Novi